GentiBio, Inc. is a biotechnology company based in Cambridge, MA, specializing in the development of engineered regulatory T cells (Tregs) for the treatment of autoimmune, alloimmune, and inflammatory diseases. Their modular engineering platform allows them to create optimized Tregs with superior phenotypes tailored to address specific diseases, resolving key challenges in Treg therapeutics.
With a focus on scalability, GentiBio's engineering approach enhances Tregs' function and manufacturing, resulting in potent and stable therapeutics. Their goal is to help patients live better lives by providing tailored treatments that target specific tissues for optimal efficacy and safety.
Generated from the website